A phase II study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with metastatic colorectal cancer who failed two prior standard chemotherapies

Category Primary study
JournalAnnals of Oncology
Year 2024
This article has no abstract
Epistemonikos ID: 2a5ba7998652a49026e5f2efb615b551077712b2
First added on: Feb 19, 2025